TNF Pathway-Mediated Tolerogenic T-Cell Trajectory Driven by Allergen Immunotherapy

Area of Science:

• Immunology
• Allergy Research
• T-cell Biology

Background:

• Allergen immunotherapy (AIT) aims to restore immune tolerance and prevent asthma.
• Early AIT involves T-cell exhaustion and induction of IL-17 and FOXP3 expressing T cells.
• Investigating the immune transition during AIT is crucial for understanding clinical outcomes.

Purpose of the Study:

• To investigate the dynamic shift from type-3 immunity to a regulatory state during allergic inflammation under AIT.
• To analyze the subsequent dysfunction of effector cells during AIT.
• To understand the cellular and molecular mechanisms underlying AIT's efficacy.

Main Methods:

• Utilized human and experimental models of allergic airway inflammation.
• Assessed T-cell populations (Treg, Tr17, Th17) using flow cytometry and proliferation assays.
• Employed single-cell transcriptomics on human blood samples to identify transcriptional signatures.

Main Results:

• AIT rebalanced Treg and Tr17 populations, enhancing their proliferation while Th17 cells remained impaired.
• Single-cell transcriptomics identified Tr17 cells as transitional states between pro-inflammatory and regulatory T-cell programs post-AIT.
• AIT reprogrammed intracellular networks, highlighting TNF/LTA signaling in mediating tolerance.

Conclusions:

• AIT enhances regulatory dominance, promotes Tr17 cell plasticity, and utilizes TNF/TNFR2 signaling for tolerance.
• Targeting Th17 cell functional impairment could improve AIT efficacy for allergic airway diseases.
• Understanding AIT's cellular dynamics offers new strategies for immune restoration and improved patient outcomes.